Shift from Public to Private Healthcare in the UK

This report examines the transition from public to private healthcare in the UK, focusing on its implications for life science companies. It outlines how the rise of private payers, including insurers and self-paying consumers, is reshaping access pathways in the healthcare market. The document discusses the uneven nature of this shift, influenced by various factors such as public system delays and reimbursement challenges. Two case studies are presented: obesity, where private market growth is significant due to limited public access, and oncology, where delays in NHS services are driving patients toward private diagnostics. The report emphasizes the need for life science companies to adapt their strategies to engage effectively with private payers, highlighting the importance of understanding patient behavior and market dynamics. It concludes with considerations for developing dual-track strategies that integrate both public and private healthcare pathways to optimize patient access and company growth.